This article is part of the supplement: Basic science, rationale, background and future of abatacept

Highly Accessed

Review

The evolving clinical profile of abatacept (CTLA4–Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis

Eric M Ruderman^* and Richard M Pope

* Corresponding author: Eric M Ruderman e-ruderman@northwestern.edu

Arthritis Research & Therapy 2005, 7(Suppl 2):S21-S25 doi:10.1186/ar1688

No comments have yet been made on this article.